论文部分内容阅读
目的探索超声引导下经皮无水乙醇治疗原发性肝癌的终点及疗效。方法 104例肝癌患者随机分成两组,治疗组72例注射次数不限,注射量以达到不能注射为限;对照组32例注射次数按瘤体直径cm2计算,注射量以瘤体大小与回归方程系数乘积来确定。结果治疗结束后两组患者瘤体均有不同程度的缩小,AFP下降明显,肝区疼痛有不同程度的缓解;所有患者治疗后均未出现重要脏器功能明显异常和邻近组织脏器损伤等严重并发症,随访3年治疗组肝癌复发率低于对照组,差异具有显著性意义(P<0.05)。结论应用超声引导下经皮乙醇消融治疗肝癌疗效明显,安全可靠,在瘤体部位注射无水乙醇达到最大量可提高肝癌AFP阴转率、降低复发率、可使肿瘤病灶达到最大限度的缩小,患者生存期延长,生活质量明显提高。
Objective To explore the end point and curative effect of ultrasound-guided percutaneous ethanol treatment of primary liver cancer. Methods A total of 104 patients with hepatocellular carcinoma were randomly divided into two groups. In the treatment group, the number of injections was not limited to 72, and the injection volume was limited to not injection. The number of injections in the control group was calculated according to the diameter of the tumor. Cm2. Coefficient product to determine. Results After the treatment, the tumors of the two groups were reduced to different extents, the AFP decreased significantly, and the pain in the liver area was alleviated to some extent. No significant abnormalities of vital organs and adjacent organ tissues were found in all the patients after treatment The follow-up of 3-year follow-up of liver cancer recurrence rate was lower than the control group, the difference was significant (P <0.05). Conclusion The application of ultrasound-guided percutaneous ethanol ablation in the treatment of liver cancer has obvious curative effect, which is safe and reliable. The injection of absolute ethanol in the tumor site can achieve the maximum conversion rate of AFP, reduce the recurrence rate and reduce the tumor focus to the maximum. Patients with prolonged survival, quality of life improved significantly.